How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

909 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. (PubMed)

A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. To evaluate in a pilot single-blind randomized controlled clinical trial the efficacy of an integrated treatment with rivastigmine transdermal patch (RTP) and cognitive stimulation (CS) in Alzheimer's disease (AD) patients at 6-month follow-up.We enrolled 90 patients with an age ≥65 years admitted to the outpatient Alzheimer's

2014 International Journal of Geriatric Psychiatry

82. Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study. (PubMed)

Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study. Higher-level gait disorder (HLGD) in older adults is characterized by postural instability, stepping dysrhythmicity, recurrent falls and progressive immobility. Cognitive impairments are frequently associated with HLGD.The aim of this study was to compare gait and cognitive performance before and after the use of rivastigmine in patients with HLGD, free from cognitive impairment (...) or Parkinsonism.Fifteen non-demented patients with HLGD (age 79.2 ± 5.9 years; 11 women; Mini-Mental State Examination [MMSE] 28.3 ± 1.4) received escalating doses of rivastigmine for 12 weeks in an open-label, pilot study. They were assessed before and after treatment (week 0 and week 12), and after a 4-week washout period (week 16). Assessments included the Mindstreams computerized neuropsychological battery, Activities-specific Balance Confidence Scale, State-Trait Anxiety Inventory, Geriatric Depression Scale

Full Text available with Trip Pro

2014 Drugs in R&D

83. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. (PubMed)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. Alzheimer's disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study aimed to determine the effects of two formulations of RV [transdermal

Full Text available with Trip Pro

2014 Frontiers in aging neuroscience

84. Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. (PubMed)

Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. The role of currently available drugs for Alzheimer's disease (AD) has been controversial, with some national formularies restricting their use, and health economists questioning whether the small clinical effects are economically worthwhile.To estimate the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine

2014 Journal of Alzheimer's disease : JAD

85. Cognitive Function in Early Clinical Phase Huntington Disease after Rivastigmine Treatment. (PubMed)

Cognitive Function in Early Clinical Phase Huntington Disease after Rivastigmine Treatment. In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected (...) to be impaired in early phase HD.Eighteen (18) HD patients entered the study and were randomly allocated to the rivastigmine and placebo group. All subjects underwent neuropsychological assessment at baseline. Follow-up neuropsychological assessment was applied after 6 months of rivastigmine or placebo treatment. Eighteen (18) healthy controls entered the study to control for practice effect and underwent neuropsychological assessment at baseline and after 6 months, without treatment. The neuropsychological

2014 Psychiatria Danubina

86. Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Brain (...) Changes by Rivastigmine According to Butyrylcholinesterase Alleles The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02063269 Recruitment Status : Unknown Verified May 2015 by Jun Young Lee, Seoul National University Hospital. Recruitment status was: Active, not recruiting First Posted : February 14

2014 Clinical Trials

87. Rivastigmine From Capsules to Patch: Therapeutic Advances in the Management of Alzheimer’s Disease and Parkinson’s Disease Dementia (PubMed)

Rivastigmine From Capsules to Patch: Therapeutic Advances in the Management of Alzheimer’s Disease and Parkinson’s Disease Dementia To discuss the pharmacology, mechanism of action, and chemical properties of the cholinesterase inhibitor (ChEI) rivastigmine; to provide a rationale for transdermal delivery and supportive clinical data, along with practical guidance on rivastigmine patch use in Alzheimer's disease and Parkinson's disease dementia.Pivotal studies of rivastigmine capsules (...) and patch were identified using PubMed and the rivastigmine US prescribing information. PubMed searches were performed in 2013 using rivastigmine as a keyword.English-language articles related to rivastigmine considered of relevance to primary care physicians were included.Pharmacologic differences exist between rivastigmine and ChEIs. Clinical studies demonstrate symptomatic efficacy of oral rivastigmine across all stages of Alzheimer's disease and mild-to-moderate Parkinson's disease dementia. However

Full Text available with Trip Pro

2014 The Primary Care Companion for CNS Disorders

88. Rivastigmine Actavis

Rivastigmine Actavis 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union 6 June 2011 EMA/454217/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Rivastigmine Actavis International nonproprietary name: Rivastigmine Procedure No. EMEA/H/C/2036 Assessment Report as adopted by the CHMP with all information (...) an application for Marketing Authorisation to the European Medicines Agency (EMA) for Rivastigmine Actavis, through the centralised procedure falling within the scope of the Article 3 (3) – ‘Generic of a Centrally authorised product’ of Regulation (EC) No. 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24/09/2009. The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which

2011 European Medicines Agency - EPARs

89. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

2008 DARE.

90. Rivastigmine - Dementia (Alzheimer's type)

Rivastigmine - Dementia (Alzheimer's type) CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION RIVASTIGMINE PATCH (Exelon ™ Patch – Novartis Pharmaceuticals Canada Inc.) Description: Exelon ™ Patch contains rivastigmine, a reversible cholinesterase inhibitor that is approved for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. Dosage Forms: Exelon Patch 5 contains 9 mg/5 cm 2 and releases 4.6 mg/24 hours. Exelon Patch 10 (...) -related adverse events when compared with placebo. 3. The Committee had concerns regarding the cost-effectiveness of Exelon Patch relative to best supportive care. Summary of Committee Considerations: The Committee considered a systematic review of double-blind randomized controlled trials (RCTs) in patients with mild to moderate dementia of the Alzheimer’s type. One trial of 24 weeks duration comparing Exelon Patch 10 with oral rivastigmine 6 mg given twice daily or placebo met the inclusion criteria

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

91. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. (PubMed)

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD).Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD

2013 American journal of Alzheimer's disease and other dementias

92. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. (PubMed)

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine.Total 56 patients aged 50-75 years, suffering from dementia, were allocated into one of the two treatments: group 1) Ginkgo biloba (120 mg daily dose); group 2) rivastigmine (4.5 mg daily dose) in a 24 (...) -week randomized double blind study. The degree of severity of dementia was assessed by the Seven Minute test and the Mini-Mental State Examination.Our results confirm the clinical efficacy of rivastigmine in the dementia of the Alzheimer type, comparing to Ginkgo biloba. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type.Our study

2013 JPMA. The Journal of the Pakistan Medical Association

93. Rivastigmine patch and massage for Alzheimer's disease patients. (PubMed)

Rivastigmine patch and massage for Alzheimer's disease patients. 23551354 2013 11 05 2015 11 19 1447-0594 13 2 2013 Apr Geriatrics & gerontology international Geriatr Gerontol Int Rivastigmine patch and massage for Alzheimer's disease patients. 515-6 10.1111/ggi.12010 Satoh Sachiko S Kajiwara Mutsuko M Kiyokawa Emi E Toukairin Yoshiko Y Fujii Masahiko M Sasaki Hidetada H eng Comparative Study Letter Randomized Controlled Trial Japan Geriatr Gerontol Int 101135738 1447-0594 0 Cholinesterase (...) Inhibitors 0 Phenylcarbamates PKI06M3IW0 Rivastigmine IM Activities of Daily Living Aged, 80 and over Alzheimer Disease drug therapy psychology Behavioral Symptoms Cholinesterase Inhibitors administration & dosage Cognition drug effects Female Humans Interpersonal Relations Male Massage Mental Status Schedule Phenylcarbamates administration & dosage Rivastigmine Tomography, X-Ray Computed methods Transdermal Patch 2013 4 5 6 0 2013 4 5 6 0 2013 11 6 6 0 ppublish 23551354 10.1111/ggi.12010

2013 Geriatrics & gerontology international

94. Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. (PubMed)

Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. The cholinesterase inhibitor rivastigmine is approved for the treatment of mild to moderate Alzheimer's disease. However, it is not possible to predict which individuals will benefit from treatment. This retrospective analysis of an international, 24-week, randomized, double-blind trial aimed to identify the percentage of persons with Alzheimer's disease who have a sustained response (...) with rivastigmine patch, rivastigmine capsules, or placebo; to determine the magnitude of the sustained treatment response; and to investigate baseline patient characteristics predictive of the observed sustained response.Patients who improved on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL) at week 16 and maintained at least the week 16 improvement at week 24 were identified as sustained responders

Full Text available with Trip Pro

2013 The Primary Care Companion for CNS Disorders

95. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. (PubMed)

Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. Even with optimal dopaminergic treatments, many patients with Parkinson's disease (PD) are frequently incapacitated by apathy prior to the development of dementia. We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy in dementia-free, non-depressed patients (...) with advanced PD.We performed a multicentre, parallel, double-blind, placebo-controlled, randomised clinical trial (Protocol ID: 2008-002578-36; clinicaltrials.gov reference: NCT00767091) in patients with PD with moderate to severe apathy (despite optimised dopaminergic treatment) and without dementia. Patients from five French university hospitals were randomly assigned 1:1 to rivastigmine (transdermal patch of 9.5 mg/day) or placebo for 6 months. The primary efficacy criterion was the change over time

2013 Neurosurgery and Psychiatry

96. The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. (PubMed)

The effect of rivastigmine on the LPS-induced suppression of GnRH/LH secretion during the follicular phase of the estrous cycle in ewes. This study was designed to determine the effect of a potent subcutaneously injected acetylcholinesterase inhibitor, rivastigmine (6mg/animal), on the gonadotropin-releasing hormone (GnRH)/luteinizing hormone (LH) release during inflammation induced by an intravenous lipopolysaccharide (LPS) (400ng/kg) injection in ewes during the follicular phase (...) of the estrous cycle. The results are expressed as the mean values from -2 to -0.5h before and +1 to +3h after treatment. Rivastigmine decreased the acetylcholinesterase concentration in the blood plasma from 176.9±9.5 to 99.3±15.1μmol/min/ml. Endotoxin suppressed LH (5.4±0.6ng/ml) and GnRH (4.6±0.4pg/ml) release; however, the rivastigmine injection restored the LH concentration (7.8±0.8ng/ml) to the control value (7.8±0.7ng/ml) and stimulated GnRH release (7.6±0.8pg/ml) compared to the control (5.9±0.4pg/ml

2013 Animal reproduction science

97. A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. (PubMed)

A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD).Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD

Full Text available with Trip Pro

2013 CNS neuroscience & therapeutics

98. Rivastigmine for vascular cognitive impairment. (PubMed)

Rivastigmine for vascular cognitive impairment. Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico-pathological processes: multi-infarct dementia, single strategic infarct dementia and subcortical dementia. Not all victims fulfil strict (...) criteria for dementia and may be significantly cognitively impaired without memory loss, when the term vascular cognitive impairment (VCI) is more useful. Currently, no established standard treatment for VCI exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that cholinesterase inhibitors - such as rivastigmine - which are beneficial in Alzheimer's disease, may also be beneficial for VCI.To assess the efficacy

Full Text available with Trip Pro

2013 Cochrane database of systematic reviews (Online)

99. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. (PubMed)

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. Randomized clinical trials have evaluated the efficacy of acetylcholinesterase inhibitors (AChE-Is) and memantine across a wide range of Alzheimer's disease (AD) severity. However, these drugs are prescribed and reimbursed according to precise upper and lower cut off scores of cognitive tests.To verify whether the efficacy of pharmacological treatment had any

2013 Journal of Alzheimer's disease : JAD

100. Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. (PubMed)

Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after 3 months of ChEI treatment and were compared with 15 age- and sex-matched neurologically healthy (...) with cognitive impairment show numerous regions of decreased spontaneous brain function compared with controls, and rivastigmine is associated with performance-related normalization in the left frontal cortex function.© 2013 International Parkinson and Movement Disorder Society.

Full Text available with Trip Pro

2013 Movement Disorders

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>